Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCKAR | P32238 | 3/20 | 0.41 |
| ▸ | CCKBR | P32239 | 3/20 | 0.41 |
| ▸ | ACE | P12821 | 1/20 | 0.40 |
| ▸ | AKT1 | P31749 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 6/20 | 0.39 |
| ▸ | CTSK | P43235 | 5/20 | 0.39 |
| ▸ | CTSB | P07858 | 2/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 5/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.38 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.38 |
| ▸ | APP | P05067 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6477645 | 0.89 | CCKAR (0.40) | CCKARCCKBRACEAKT1CTSS | |
| SCHEMBL6477582 | 0.88 | GNRHR (0.49) | CCKARCCKBR | |
| SCHEMBL13995047 | 0.68 | GNRHR (0.52) | ATMAPP | |
| SCHEMBL1529787 | 0.66 | PTPN1 (0.55) | ACECTSSCTSKCTSBCTSL | |
| SCHEMBL4584520 | 0.66 | PTPN1 (0.55) | ACECTSSCTSKCTSBCTSL | |
| SCHEMBL5665458 | 0.66 | ATM (0.44) | ACEAKT1CTSSCTSKCTSB | |
| SCHEMBL30928920 | 0.66 | ALDH1A1 (0.53) | — | |
| SCHEMBL27207214 | 0.65 | PTPN1 (0.52) | ACECTSSCTSKCTSBCTSL | |
| SCHEMBL27203728 | 0.65 | PTPN1 (0.52) | ACECTSSCTSKCTSBCTSL | |
| SCHEMBL2684894 | 0.64 | CTSS (0.67) | ACEAKT1CTSSCTSKCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6951858-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2005-10-04 | — | — | US | disclosed |
| US-20050075339-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2005-04-07 | — | — | US | disclosed |
| EP-1414808-A1 | 1,2,4-TRIAZIN-3,5-DIONES AS GONADOTROPIN-RELEASING HORMONE RECEPTOR (GNRH) ANTAGONISTS | Neurocrine Biosciences, Inc. (US) | 2004-05-06 | — | — | EP | disclosed |
| US-6673796-B2 | SEXUAL DISORDERS | NEUROCRINE BIOSCIENCES, INC. | 2004-01-06 | — | — | US | disclosed |
| US-20030114455-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. | 2003-06-19 | — | — | US | disclosed |
| WO-2003011841-A1 | 1,2,4-TRIAZIN-3,5-DIONES AS GONADOTROPIN-RELEASING HORMONE RECEPTOR (GNRH) ANTAGONISTS | NEUROCRINE BIOSCIENCES, INC. (US) | 2003-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114455-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | GNRHR, GHRHR, LHCGR | CCKAR 61/4885CCKBR 70/4885ACE 2262/4885 |
| US-20050075339-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | GNRHR, LHCGR, GHRHR | CCKAR 71/4885CCKBR 46/4885ACE 2282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.